Nonetheless, Poljakovic et al. [14] reported reduced levels of GH in CSF of MS patients in comparison to healthy controls, and Gironi et al. [13] found lower GH levels in more severe MS patients during their first ten years of the disease. This evidence concerns the gene GH1 and myeloid sarcoma.